The association between chemerin and homeostasis assessment of insulin resistance at baseline and after weight reduction via lifestyle modifications in young obese adults

Clinica Chimica Acta

Volumn 421, Issue , 2013, Pages 109-115

  Lee, Mi Kyung ^a   Chu, Sang Hui ^a   Lee, Duk Chul ^b   An, Ki Yong ^a   Park, Ji Hye ^a   Kim, Dong Il ^a   Kim, Jiyoung ^a   Hong, Sunghyun ^a   Im, Jee Aee ^c   Lee, Ji Won ^b   Jeon, Justin Y ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c INTOTO Inc   (South Korea)

Author keywords

Chemerin; Exercise; Insulin resistance; Lifestyle modification; Obesity

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHEMERIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PENTRAXIN 3; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; EXERCISE; FEMALE; HOMEOSTASIS ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX DIFFERENCE; SUBCUTANEOUS FAT; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; CHEMOKINES; EXERCISE; FASTING; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIFE STYLE; MALE; OBESITY; SUBCUTANEOUS FAT; WEIGHT LOSS;

EID: 84875666449     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.02.017     Document Type: Article

References (37)

1. He Y.H., Jiang G.X., Yang Y., et al. Obesity and its associations with hypertension and type 2 diabetes among Chinese adults age 40years and over. Nutrition 2009, 25:1143-1149.
2. Li G., Chen X., Jang Y., et al. Obesity, coronary heart disease risk factors and diabetes in Chinese: an approach to the criteria of obesity in the Chinese population. Obes Rev 2002, 3:167-172.
3. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
4. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
5. Rosen E.D., Spiegelman B.M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006, 444:847-853.
6. Deng Y., Scherer P.E. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci 2010, 1212:E1-E19.
7. Wittamer V., Franssen J.D., Vulcano M., et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003, 198:977-985.
8. Vermi W., Riboldi E., Wittamer V., et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med 2005, 201:509-515.
9. Zabel B.A., Zuniga L., Ohyama T., et al. Chemoattractants, extracellular proteases, and the integrated host defense response. Exp Hematol 2006, 34:1021-1032.
10. Goralski K.B., McCarthy T.C., Hanniman E.A., et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007, 282:28175-28188.
11. Muruganandan S., Roman A.A., Sinal C.J. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res 2010, 25:222-234.
12. Muruganandan S., Roman A.A., Sinal C.J. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009, 66:236-253.
13. Bozaoglu K., Bolton K., McMillan J., et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007, 148:4687-4694.
14. Shin H.Y., Lee D.C., Chu S.H., et al. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin Endocrinol (Oxf) 2012, 77:47-50.
15. Catalan V., Gomez-Ambrosi J., Rodriguez A., et al. Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-alpha stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis 2011 Nov 10, [Epub ahead of print].
16. Zanetti M., Bosutti A., Ferreira C., et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med 2009, 9:243-248.
17. Hah Y.J., Kim N.K., Kim M.K., et al. Relationship between chemerin levels and cardiometabolic parameters and degree of coronary stenosis in Korean patients with coronary artery disease. Diabetes Metab J 2011, 35:248-254.
18. Takahashi M., Takahashi Y., Takahashi K., et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008, 582:573-578.
19. Sell H., Laurencikiene J., Taube A., et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009, 58:2731-2740.
20. Takahashi M., Okimura Y., Iguchi G., et al. Chemerin regulates beta-cell function in mice. Sci Rep 2011, 1:123.
21. Ernst M.C., Haidl I.D., Zuniga L.A., et al. Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology 2012, 153:672-682.
22. Bozaoglu K., Segal D., Shields K.A., et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009, 94:3085-3088.
23. Weigert J., Neumeier M., Wanninger J., et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010, 72:342-348.
24. Lehrke M., Becker A., Greif M., et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009, 161:339-344.
25. Chu S.H., Lee M.K., Ahn K.Y., et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 2012, 7:e34710.
26. Chakaroun R., Raschpichler M., Kloting N., et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism 2012, 61:706-714.
27. Wanninger J., Bauer S., Eisinger K., et al. Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver. Mol Cell Endocrinol 2012, 349:248-254.
28. WHO The Asia-Pacific perspective: redefining obesity and its treatment. International Association for the Study of Obesity 2000, Health Communications Australia Pty Limited on behalf of Steering Committee. S. Inoue, P. Zimmet (Eds.).
29. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
30. Weisell R.C. Body mass index as an indicator of obesity. Asia Pac J Clin Nutr 2002, 11(Suppl. 8):S681-S684.
31. Lee J.W., Lee H.R., Shim J.Y., et al. Viscerally obese women with normal body weight have greater brachial-ankle pulse wave velocity than nonviscerally obese women with excessive body weight. Clin Endocrinol (Oxf) 2007, 66:572-578.
32. Tan B.K., Chen J., Farhatullah S., et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009, 58:1971-1977.
33. Becker M., Rabe K., Lebherz C., et al. Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes 2010, 59:2898-2903.
34. Kralisch S., Weise S., Sommer G., et al. Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept 2009, 154:102-106.
35. Ogawa T., Kawano Y., Imamura T., et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring) 2010, 18:1871-1874.
36. Yoneda M., Uchiyama T., Kato S., et al. Plasma pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 2008, 8:53.
37. Jenny N.S., Arnold A.M., Kuller L.H., Tracy R.P., Psaty B.M. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009, 29:594-599.